Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

BACKGROUND: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Panés, Julián, Su, Chinyu, Bushmakin, Andrew G, Cappelleri, Joseph C, Mamolo, Carla, Healey, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323227/
https://www.ncbi.nlm.nih.gov/pubmed/25651782
http://dx.doi.org/10.1186/s12876-015-0239-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323227/
https://www.ncbi.nlm.nih.gov/pubmed/25651782
http://dx.doi.org/10.1186/s12876-015-0239-9

Ejemplares similares